Childhood DNA methylation as a marker of early life rapid weight gain and subsequent overweight by Robinson, Natassia et al.
Northumbria Research Link
Citation: Robinson, Natassia, Brown, Heather, Antoun, Elie, Godfrey, Keith, Hanson, Mark, Lillycrop, 
Karen, Crozier, Sarah, Murray, Robert, Pearce, Mark, Relton, Caroline, Albani, Viviana and Mckay, Jill  
(2021)  Childhood  DNA methylation  as  a  marker  of  early  life  rapid  weight  gain  and  subsequent  
overweight. Clinical Epigenetics, 13 (1). p. 8. ISSN 1868-7075 
Published by: BioMed Central
URL: https://doi.org/10.1186/s13148-020-00952-z <https://doi.org/10.1186/s13148-020-00952-z>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/44580/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)




Childhood DNA methylation as a marker of early life rapid weight 1 
gain and subsequent overweight 2 
N. Robinson1, H. Brown1, Elie Antoun2, Keith M Godfrey3, Mark A. Hanson2, Karen A. Lillycrop2, Sarah R. 3 
Crozier3, Robert Murray2, M.S. Pearce1, C.L. Relton4, V. Albani1,  J.A. McKay5 4 
Affiliations 5 
1. Population Health Sciences, Newcastle University Medical School, Newcastle University 6 
2. Institute of Developmental Sciences, Biological Sciences and NIHR Southampton Biomedical Research Centre, University 7 
of Southampton 8 
3. MRC Lifecourse Epidemiology Unit and NIHR Southampton Biomedical Research Centre, University of Southampton and 9 
University Hospital Southampton NHS Foundation Trust  10 
4.  MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, UK 11 




High early postnatal weight gain has been associated with childhood adiposity, however the 16 
mechanism remains unknown. DNA methylation is a hypothesised mechanism linking early life 17 
exposures and subsequent disease. However, epigenetic changes associated with high early weight 18 
gain have not previously been investigated. Our aim was to investigate the associations between 19 
early weight gain, peripheral blood DNA methylation, and subsequent overweight/obese.  20 
 21 
Data from the UK Avon Longitudinal study of Parents and Children (ALSPAC) cohort were used to 22 
estimate associations between early postnatal weight gain and epigenome-wide DNA CpG site 23 
methylation (Illumina 450K Methylation Beadchip) in blood in childhood (n= 125) and late 24 
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adolescence (n= 96).  High weight gain in the first year (a change in weight z‐scores >0.67), both 25 
unconditional (rapid weight gain) and conditional on birthweight (rapid thrive), were related to 26 
individual CpG site methylation and across regions using the meffil pipeline, with and without 27 
adjustment for cell type proportions, and with 5% false discovery rate correction. Variation in 28 
methylation at high weight gain associated CpG sites were then examined with regards to body 29 
composition measures in childhood and adolescence. Replication of the differentially methylated 30 
CpG sites was sought using whole-blood DNA samples from 104 children from the UK Southampton 31 
Women’s Survey. 32 
Results 33 
Rapid infant weight gain was associated with small (+1% change) increases in childhood methylation 34 
(age 7) for two distinct CpG sites (cg01379158 (NT5M) and cg11531579 (CHFR)). Childhood 35 
methylation at one of these CpGs (cg11531579) was also higher in those who experienced rapid 36 
weight gain and were subsequently overweight/obese in adolescence (age 17). Rapid weight gain 37 
was not associated with differential DNA methylation in adolescence. Childhood methylation at the 38 
cg11531579 site was also suggestively associated with rapid weight gain in the replication cohort.  39 
 40 
Conclusions 41 
This study identified associations between rapid weight gain in infancy and small increases in 42 
childhood methylation at two CpG sites, one of which was replicated and was also associated with 43 
subsequent overweight/obese. It will be important to determine whether loci are markers of early 44 
rapid weight gain across different, larger populations. The mechanistic relevance of these 45 









Children are becoming obese at younger ages (1), suggesting that factors in early life may play a role 53 
in obesity development. The developmental origins of health and disease (DOHaD) hypothesis 54 
proposes that early life environmental exposures have the potential to modify the risk of later-life 55 
diseases, such as obesity (2). Rapid weight gain (RWG) is an early life factor that has been 56 
consistently associated with childhood adiposity both dependently and independently of birthweight 57 
(3-5). Weight gain in the first year specifically (opposed to change in weight over periods greater or 58 
less than 1 year), has been found to be most predictive of childhood obesity (6), suggesting this is a 59 
critical period.  60 
Given the responsiveness to environmental stimuli, the capacity to alter gene expression and their 61 
stability over time, epigenetic changes are a proposed mechanism underlying the DOHaD 62 
hypothesis. Through programming effects, epigenetic marks laid down at an early developmental 63 
stage could elicit effects at a later stage (7). DNA methylation (DNAm), is the most stable and widely 64 
studied epigenetic modification and is a key mechanism regulating gene expression. DNAm involves 65 
the covalent addition of a methyl group to cytosine residues adjacent to guanine in DNA (CpG sites) 66 
and is associated with changes in gene transcription (8). If early life factors lead to stable changes in 67 
DNAm, these changes could be used as biomarkers and to identify individuals who may benefit from 68 
intervention prior to disease onset.  69 
BMI has been associated with variation in DNAm from birth to adulthood (9-12). Epigenome-Wide 70 
Association Studies (EWAS) are a comprehensive approach to identify epigenetic variation 71 
associated with a biological trait or exposure (13, 14). In EWAS, other early life risk factors for 72 
childhood obesity such as birthweight and maternal BMI have been associated with variation in 73 
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DNAm (15, 16). To our knowledge, there have been no EWAS to date on early life rapid growth and 74 
DNAm. 75 
Our first aim was to identify DNAm changes associated with early life growth. In this study we 76 
hypothesised that early life rapid growth is associated with DNAm changes. Using epigenome-wide 77 
DNAm array data from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, we 78 
investigated if early life rapid growth is associated with variation in childhood methylation, and if 79 
methylation changes persist into adolescence. As catch up growth is more likely in low birthweight 80 
infants, we investigated rapid growth both adjusted (rapid thrive, RT) (17) and unadjusted for 81 
birthweight (rapid weight gain, RWG)(4). We also examined differential methylation in a subset of 82 
known BMI-associated CpG loci (12) with the aim of identifying differentially methylated loci more 83 
likely to be related to body composition, and by analysing fewer loci, to offset the multiple 84 
comparison problem often associated with null findings in EWAS. 85 
An important consideration is that not all children with rapid infancy weight gain will have increased 86 
adiposity in childhood (18), and previous studies have highlighted the necessity to distinguish infants 87 
at greatest risk of overweight/obesity. Therefore, we also aimed to explore if differential 88 
methylation was associated with later life BMI and overweight/obesity in those who experienced 89 
early rapid weight gain to determine potential risk markers. Finally, we sought replication in an 90 
independent cohort, the UK Southampton Women’s survey.  91 
Methods 92 
Cohort 93 
We performed our initial analysis in the Avon Longitudinal Study of Parents and Children (ALSPAC) 94 
cohort, which has detailed early life, anthropometric and epigenome-wide DNAm data at multiple 95 
time points. This ongoing longitudinal birth cohort, based in Bristol, England (UK), initially invited 96 
pregnant women resident in Avon, UK with expected dates of delivery 1st April 1991 to 31st 97 
December 1992 (19, 20). There were 14,541 initial pregnancies enrolled (for these at least one 98 
questionnaire has been returned or a “Children in Focus” clinic had been attended by 19/07/99), 99 
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with a total of 14,676 foetuses, resulting in 14,062 live births and 13,988 children who were alive at 100 
1 year of age. 101 
The cohort have had extensive questionnaires as well as clinical assessments (including measures of 102 
height & weight) throughout childhood. The Accessible Resource for Integrated Epigenomic Studies 103 
(ARIES) is a subset of the ALSPAC cohort (21), for which epigenome-wide DNAm analysis was carried 104 
out for 1,018 mother and child pairs. Ethical approval for the study was obtained from the ALSPAC 105 
Ethics and Law Committee and local research ethics committees. The study website contains details 106 
of all the data that are available through a fully searchable data dictionary accessible 107 
at www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.  108 
 109 
Early life data 110 
Birthweight and gestational age were taken from medical records. At 12 months, infants were 111 
weighed using the Seca 724 (or Seca 835 for children who could only be weighed with a parent). 112 
Birthweight and weight-for-age (12 months) z-scores were calculated using the British 1990 growth 113 
reference (22), and were used to determine the rapid growth variables: RWG and RT. Whilst 114 
birthweight is an important factor in childhood obesity (23), it has previously been examined in the 115 
ALSPAC cohort (15, 24). However, in order to differentiate the effects of birthweight on early life 116 
rapid growth, both RWG (not conditional on birthweight) and RT (conditional on birthweight) in the 117 
first year were examined (Figure 1). Conditional weight gain (also known as thrive index), accounts 118 
for normal catch-up growth from low birthweight as a linear measure of weight gain adjusted for 119 
regression to the mean (17). Rapid thrive was determined as z-score12m − r × z-scorebirth (17), where r 120 
is the cohort regression coefficient (r=0.35) of birthweight-z on weight-z (12 months).  RWG is most 121 
often defined as a >+0.67 standard deviation change in weight-for-age z-score, equivalent to 122 
crossing a growth centile band on a standard child growth chart (4). Both RWG and RT were analysed 123 




Anthropometric data 126 
Anthropometric measures at (approximately) age 7 and 17 were also analysed as outcomes in 127 
analyses. At age 7, height was measured to the nearest millimetre without shoes or socks using a 128 
Holtain stadiometer (Holtain Ltd, Crymych, Pembs, UK), whilst weight was measured using Tanita 129 
THF 300GS body fat analyser and weighing scales (Tanita UK Ltd, Yewsley, Middlesex, UK). At age 17, 130 
height was measured with a Harpenden stadiometer to the nearest mm, and weight using the Tanita 131 
Body Fat Analyser (Model TBF 401A) to the nearest 50g. 132 
BMIz and overweight/obese were examined as outcomes at both time points. Body mass index 133 
(BMI) was calculated as weight (kg) divided by height (m) squared and was transformed to age and 134 
sex standardised BMI z-scores using the British 1990 growth reference with the zanthro program in 135 
Stata (25). Clinical cut-offs were used to determine weight categories, whereby healthy weight was 136 
between the 2nd and 91st centiles, and overweight/obese as greater than the 91st centile (26) . 137 
 138 
Epigenetic data 139 
ALSPAC collected (peripheral) blood at ages 7 and 17 and DNA was extracted. Epigenome-wide 140 
DNAm at specific CpG sites was measured for ~1000 individuals using the 141 
Infinium® HumanMethylation450K BeadChip assay (Illumina, Inc., CA, USA). DNAm data were pre-142 
processed, including background correction and subset quantile normalization using the pipeline 143 
described by Touleimat and Tost (27) (further details in the ARIES cohort profile (21)). Estimation of 144 
white blood cell counts (CD8T cells, CD4T cells, Natural Killer, B cells, Monocytes and 145 
Granulocytes) was done using the Houseman algorithm (28). Cross-reactive and polymorphic probes 146 
identified by Chen et al., (29) and probes on sex chromosomes were removed prior to downstream 147 
analysis (n=453,723 probes). Due to few participants with non-Caucasian or missing ethnicity, and 148 
few non-singleton births, these were removed. 149 
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Statistical analysis 150 
To examine if childhood or adolescent DNAm in peripheral blood (around ages 7 and 17) was 151 
associated with early life rapid growth, three different analyses were undertaken, including: analysis 152 
of differentially methylation positions, differentially methylated regions, and differentially 153 
methylated positions in a subset of candidate loci.  154 
For each analysis, DNAm was the outcome and the independent variable was either RWG or RT, with 155 
models adjusted for sex and age at blood collection. Cell type composition is a significant source of 156 
variation in DNAm analysis (30), however chronic, low level inflammation is a component of the 157 
obesity phenotype, therefore, to find novel biomarkers associated with this phenotype, DNAm was 158 
investigated in models with and without adjustment for cell composition (all 6 cell types). Correction 159 
for multiple testing was applied using a false discovery rate (FDR) threshold of p<0.05 (31).  160 
First, epigenome-wide association studies (EWAS) were conducted for rapid growth (first year) and 161 
DNAm outcomes in childhood (age 7.4) and adolescence (age 17.6) in the Meffil R package (32). 162 
Estimation of differentially methylated sites was carried out using the beta values as the outcome 163 
and rapid growth (RWG/RT) as the exposure adjusted for age and sex. Surrogate variable analysis 164 
(SVA) and independent surrogate variable analysis (ISVA) methods were utilised to control for 165 
unmodelled or unknown confounding factors (such as batch) (33, 34). Meffil simultaneously 166 
computes unadjusted, adjusted, SVA and ISVA models, thereby allowing results to be compared (32). 167 
In order to minimise the influence of outliers in methylation data, beta values were winsorised at the 168 
level of 5% (95th percentile cut-off).  169 
Second, in order to detect a DNAm signature of rapid growth, differentially methylated regions 170 
(DMRs) were analysed. DMRs, which are stretches or clusters of neighbouring CpG probes, may have 171 
more of a functional effect on gene expression than individual CpG loci (35). Additionally, if changes 172 
in DNAm are small but persistent across a region, there may be more statistical power to detect 173 
them collectively as DMRs (36). The R package DMRcate was used for the estimation of DMRs (37), 174 
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using the M-values and default settings. The surrogate variables (that were calculated using Meffil in 175 
the EWAS models) were included as covariates in the DMR models. 176 
Finally, in order to focus on loci with anticipated associations with adiposity, a candidate gene 177 
approach was taken using a subset of CpG sites robustly associated with BMI. The candidate sites 178 
were selected from a large-scale meta-analysis EWAS which utilised data from multiple cohorts of 179 
European and Indian-Asian descent (12). After validation, 187 CpG sites were associated with BMI. 180 
We conducted EWAS for both RWG and RT using the 187 identified CpG sites as candidates, at both 181 
time points using the Meffil R package (32). 182 
Any significantly differentially methylated sites were analysed further to determine if DNAm was 183 
also associated with body composition (at age 7 and 17). Using linear regression, significant CpG 184 
sites were examined with respect to childhood and adolescent BMI (dependent variable). Similarly, 185 
as differentially methylated loci were identified in the RWG EWAS, the CpG sites were also examined 186 
with regards to RT in adjusted linear models. All models were adjusted for age and sex. Differences 187 
in DNAm by phenotype (RWG, overweight/obese) were assessed using ANOVA tests between groups 188 
(with Bonferroni correction for multiple testing).  189 
All EWAS and bioinformatic analyses were done in Rstudio version 3.3.2. The human reference 190 
genome (GRCh37/hg19 assembly) was used to determine the location and features of the gene 191 
region using the UCSC Genome Browser (38). Recoding of the variables and statistical analysis of 192 
differentially methylated sites was done in Stata version 15.1 (StataCorp, College Station, Texas, 193 
USA). 194 
Replication analysis 195 
 196 
CpG sites with FDR P-values <0.05 were carried forward for replication using DNA methylation data 197 
from the children from the Southampton Women’s Survey (SWS), a similar UK-based cohort (39). 198 
Blood methylation measures (EPIC array) and early life weight data for 104 of the SWS children (age 199 
= 11-13 years, all Caucasian) were available. Further details of the replication cohort and 200 
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methylation data processing are provided in the Supplementary text. The exact same models were 201 
estimated for the differentially methylated CpG sites in childhood (age 11-13) and early life rapid 202 
growth (RWG and RT, 0-12 months) using the meffil R package with both SVA and ISVA. Models were 203 
all adjusted for child’s sex and age at DNAm measurement and were run with and without 204 
adjustment for cell type composition. 205 
 206 
Results 207 
Descriptive characteristics  208 
Early life growth and 450K array data were available for 125 ALSPAC children at age 7 and 96 at 209 
age 17 (Table 1). Weight at 12 months was measured in a fraction (n=1,432, 9.3%) of ALSPAC 210 
children, thereby limiting the sample size for the methylation analysis. The ARIES sub-sample was 211 
mostly representative of the main study population; however, ARIES mothers were slightly older, 212 
less likely to have a manual occupation and were less likely to smoke during pregnancy (21). At age 213 
7, 13% of study members were overweight/obese, and 19% were at age 17 (Supplementary Table 1).  214 
 215 
Table 1 The proportion of individuals in the study sample with RWG or RT at age 7 and 17  216 
  
Models adjusted for cell counts 
 
Models not adjusted for cell counts 
Age Variable Total No % Yes % 
 
Total No % Yes % 
7 RWG 116 75 64.7 41 35.3  125 84 67.2 41 32.8 
 RT 116 65 56.0 51 44.0  125 73 58.4 52 41.6 
17 RWG 89 54 60.7 35 39.3  96 61 63.5 35 36.5 
 RT 89 50 56.2 39 43.8  96 56 58.3 40 41.7 
Presented for models adjusted or unadjusted for cell counts. RWG, rapid weight gain; RT, rapid thrive. 217 
94/125 (75%) with measures at age 7 had DNAm measures at age 17. 218 
 219 
EWAS results  220 
We observed associations (PFDR<0.05) between RWG and individual CpG loci at age 7. Across the 221 
adjusted models there were 4 associations identified for RWG (PFDR<0.05) corresponding to 2 unique 222 
CpG sites (Table 2). These loci were cg01379158 (NT5M) and cg11531579 (CHFR), and both were 223 
associated with a 1% increase in methylation (p=0.02) in those who had RWG. In the models without 224 
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cell counts, two of the model p values were also below the Bonferroni p value threshold (1.04x10-7). 225 
There were no associations (PFDR<0.05) between RT and individual CpG loci at age 7 in the EWAS. We 226 
examined whether methylation at the RWG-associated CpG sites was also associated with RT using 227 
regression analysis, however the magnitude of the coefficients was lower and less statistically robust 228 
than for RWG (Supplementary Table 2). There was no evidence that RWG or RT was associated (PFDR 229 
<0.1) with differential DNAm in adolescence for the EWAS, or for the 2 CpG sites identified as 230 
differentially methylated at age 7 using linear regression. In the DMR analysis, there were no overall 231 
DMRs identified; all Stouffer corrected p values were non-significant, suggesting a lack of 232 
consistency in the direction of the methylation changes. 233 
 234 
Table 2 Associations (FDR p<0.05) between individual CpG sites (age 7, n=453,723) and the early life growth 235 
in models 236 





CpG island name Model Coef SE P PFDR 
 With cell counts         
RWG 116 cg01379158 NT5M TSS200 
chr17:17206527-
17207306 
ISVA 0.011 0.0018 2.91x10-7 0.02 
 Without cell counts         
RWG 125 cg01379158 NT5M TSS200 
chr17:17206527-
17207306 
ISVA 0.011 0.0017 1.41x10-8 0.01 
RWG 125 cg11531579 CHFR Island 
chr12:133484658-
133485739 
SVA 0.011 0.0019 4.16x10-8 0.02 
RWG 125 cg11531579 CHFR Island 
chr12:133484658-
133485739 
ISVA 0.011 0.0019 1.26 x10-7 0.03 
All associations FDR p<0.05 are presented from the ISVA and SVA models, and the models with and without 237 
adjustment for cell types. Chr, chromosome; PFDR, FDR p value; P, unadjusted p value, Coef, coefficient; 238 
TSS200, transcription start site; RWG, rapid weight gain; SVA, Surrogate variable analysis, and ISVA, 239 
independent surrogate variable analysis. Bonferroni p value threshold =1.04x10-7. 240 
 241 
The candidate gene analysis 242 
The aim of the candidate gene analyses was to select CpG loci already known to be associated with 243 
the outcome phenotype of interest (body composition). Using a smaller subset of loci as candidates 244 
has the advantage of reducing the stringent p value threshold when correcting for multiple tests. 245 
The candidate gene analysis utilised findings from a consortium, which integrated data from 4 246 
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discovery cohorts and replicated findings in 9 cohorts, and found 187 validated methylation markers 247 
associated with BMI (12).  248 
The associations between the candidate CpG loci (n=187) and early life rapid growth were examined 249 
using the ALSPAC methylation childhood and adolescent data, however there were no associations 250 
identified (Bonferroni p value>3x10-4). 251 
 252 
Investigating phenotypic differences in DNAm associated with RWG 253 
 254 
Methylation at either site was not directly associated with BMIz at age 7 or 17 in regression analyses. 255 
For both CpG sites, highest methylation was in those who had RWG and were subsequently 256 
overweight/obese (compared to healthy weight), both in childhood and adolescence 257 
(Supplementary Table 3). At the cg11531579 site, childhood methylation was higher in those who 258 
were subsequently overweight/obese (age 17) and had RWG compared to those who did not have 259 
RWG (Figure 2, ANOVA p<0.05). However, the sample sizes for these groups were small and 260 
therefore results are inconclusive. 261 
 262 
Furthermore, those who were healthy weight at age 7 but were overweight/obese at age 17 had 263 
higher methylation at age 7 (Figure 3). Whereas, those who had RWG but were a healthy weight (at 264 
either time point) had consistently lower levels of methylation. On average, methylation was lower 265 
in those who did not have RWG regardless of weight status. Although group sizes were small (n=6), 266 
methylation at age 7 could have indicated future risk of overweight/obesity in the ‘high-risk’ group. 267 
 268 




Overall, the two CpG sites which were positively associated with RWG tended to increase in 271 
methylation over time from childhood to adolescence within individuals (Figure 4). However, when 272 
stratifying by RWG, in those who had RWG there was a decrease in methylation over time compared 273 
to those who did not experience RWG, particularly for cg11531579 (p<0.001, Figure 4).  274 
 275 
Childhood methylation in the replication cohort 276 
 277 
Replication of the significant CpG sites was carried out using a similar UK-based cohort with data on 278 
growth in early life and epigenetic data in childhood (n=104 at age 12). Compared to ALSPAC 279 
children, fewer experienced rapid growth in the first year in the SWS cohort; 29.7% had RWG 280 
(30/101) and 22.8% (23/101) had RT. Similar to the findings in ALSPAC, there was evidence of an 281 
association between RWG and DNA methylation at cg11531579 in the ISVA (p=0.02) and SVA 282 
(p=0.04) models, although the coefficients were smaller (0.005 and 0.004 in the ISVA and SVA 283 
models respectively) (Table 3). There was no association for the either the cg01379158 site or the RT 284 
models. 285 
 286 
Table 3 Associations between early life rapid growth and childhood methylation in the replication cohort 287 
(SWS children age 11-13, n=104) 288 
Models with cell counts 
 ISVA  SVA 
Exposure CpG site 
Nearest 
gene 
Coef SE P   Coef SE P 
RWG cg11531579 CHFR 0.0045 0.0020 0.02  0.0045 0.0021 0.04 
RWG cg01379158 NT5M 0.0004 0.0029 0.90  -0.0022 0.0026 0.40 
          
RT cg11531579 CHFR 0.0022 0.0026 0.39  0.0029 0.0024 0.23 
RT cg01379158 NT5M -0.0002 0.0036 0.96  -0.0030 0.0029 0.31 
                   
Models without cell counts         
RWG cg11531579 CHFR 0.0005 0.0020 0.82  -0.0002 0.0020 0.92 
RWG cg01379158 NT5M 0.0019 0.0023 0.40  0.0020 0.0023 0.40 
          
RT cg11531579 CHFR -0.0013 0.0020 0.52  -0.0020 0.0022 0.37 
RT cg01379158 NT5M 0.0043 0.0027 0.12  0.0018 0.0026 0.48 
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P, unadjusted p value, Coef, coefficient; RWG, rapid weight gain; SVA, Surrogate variable analysis, and ISVA, 289 
independent surrogate variable analysis.  290 
 291 
Genomic location of the differentially methylated CpG sites 292 
The CpG site; cg01379158 was located upstream of the transcriptional start site in a CpG island 293 
(chr17:17206527-17207306). The nearest gene to cg01379158 is NT5M, also known as 5',3'-294 
Nucleotidase, Mitochondrial.  The second CpG site (cg11531579), was positively associated with 295 
RWG (pFDR<0.05, Table 2). This CpG (cg11531579) is located within a CpG island on chromosome 12: 296 
upstream 30+ kilobases is the protein coding gene Checkpoint With Forkhead And Ring Finger 297 
Domains (CHFR) (Table 2), whilst 558 base pairs downstream, is a small (2 exons) non-coding region 298 






In this study, we identified that RWG in the first year of life was associated with small but significant 305 
increases in childhood DNAm (age 7) at two CpG sites (cg01379158 and cg11531579). The highest 306 
levels of methylation at the cg11531579 locus (age 7) were in those who had RWG and were either 307 
currently (age 7) or subsequently overweight/obese (age 17). Furthermore, there was suggestive 308 
evidence that this site was differentially methylated in the replication cohort. We did not find 309 
evidence of differentially methylated regions, of differential methylation associated with RT, or of 310 
differentially methylated BMI-associated candidate sites. 311 
Interpretation and comparison with previous findings   312 
 313 
To our knowledge this is the first EWAS to identify differential DNAm associated with early life rapid 314 
weight gain. DNAm at the locus near CHFR (cg11531579) was higher in those who had RWG and who 315 
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were overweight/obese in childhood or adolescence. Early life RWG was associated with small 316 
changes in childhood methylation, but not with methylation in adolescence, which could have been 317 
partly due to a smaller sample size or a lack of persistence in the differential DNAm seen in early life.  318 
Indeed, in those who had RWG there was a decrease in methylation over time (age 7 to 17), which 319 
may reflect the ‘recovery’ of hypermethylation in childhood. This phenomenon of attenuation of 320 
DNAm over time from signals detected in early life has been reported previously (24). There is the 321 
possibility that methylation changes may be greater earlier in childhood closer to the timing of the 322 
exposure. 323 
There are inherent links between birthweight and postnatal growth, and birthweight associated 324 
DNAm changes are also often related to growth control (40). Rapid thrive accounts for catch-up 325 
growth from low birthweight, whereas RWG includes some of the effects of low birthweight. 326 
Although birthweight influences RWG, associations between RWG and adiposity remain after 327 
adjustment for birthweight (41). As associations were stronger between DNAm (at the identified 328 
CpG sites) and RWG (rather than RT), it is plausible that methylation at these sites also encompasses 329 
some of the effects of catch-up growth from low birthweight. 330 
Neither early life growth nor birthweight have been previously associated with DNAm at either of 331 
the identified sites. We searched the EWAS Catalogue (http://ewascatalog.org/) to assess whether 332 
any of the CpG sites had been previously identified in other EWAS, with results suggesting that both 333 
of these loci may be linked to bone composition and cholesterol metabolism, factors which could 334 
plausibly be linked to growth. As the DNAm changes identified were small, it is perhaps speculative 335 
to discuss the impact on gene expression.  336 
The cg11531579 site, which was positively associated with RWG in ALSPAC and the SWS children, 337 
has nearby transcripts with cancer-associated roles (42-48).  The CHFR (cg11531579) gene encodes a 338 
E3 ubiquitin-protein ligase which regulates the cell cycle at the antephase checkpoint (prior to cell 339 
division) (42). Differential epigenetic regulation of CHFR has been identified in cancer as a result of 340 
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promoter hypermethylation (43, 44), or deacetylation of histones in the promoter region (45), 341 
however it is unclear whether changes in expression are a cause or consequence of cancer. The CpG 342 
site is located within a DNAse I hypersensitivity cluster, which may suggest a transcription factor 343 
binding region, and a H3K27Ac histone mark, which is often found near regulatory elements and is 344 
thought to be a transcription enhancer, suggesting regulatory functions. Downstream of cg11531579 345 
is AK055957, a small non-coding RNA regulatory sequence, with an uncharacterised biological role. 346 
Recently, this CpG (in combination with others) has been identified as a potential DNAm biomarker 347 
for use in detection panels for hepatocellular carcinoma (46) and pancreatic ductal adenocarcinoma 348 
(47), and is differentially methylated in children with acute myeloid leukaemia post-chemotherapy (-349 
0.24 change in beta value, p=0.004) (48). These findings suggest this locus may have a role in 350 
carcinogenesis, which may suggest a weak link with rapid growth. 351 
The cg01379158 site is located in the transcriptional start site of the NT5M gene, a gene involved in 352 
nucleotide metabolism. The gene is located on chromosome 17 in the Smith-Magenis syndrome-353 
critical region, which is a rare condition characterised by inverse circadian rhythm and disturbed 354 
sleep, factors which have also been linked to child obesity (49, 50). At this CpG site there was no 355 
evidence of differential methylation in the SWS cohort, and methylation at the cg11531579 site was 356 
around half that observed in ALSPAC. There are several possible reasons for this, such as the 357 
moderate sample sizes, or smaller proportion of those who had rapid growth in the SWS. From the 358 
ALSPAC data it was evident that there is loss of methylation over time (age 7-17) at these loci in 359 
those with RWG, therefore as the SWS were also slightly older (+5 years) this may also explain less 360 
differential methylation. This may suggest that a biomarker for early rapid growth could have 361 
greater utility in early childhood and warrants further investigation in younger cohorts.  362 
There were no associations between previously reported BMI-related CpG sites and RWG or RT 363 
arising from our candidate analysis, which could be for various reasons. First, the candidate loci 364 
mapped to genes with specific roles, which could be different to the mechanisms and pathways of 365 
RWG. Secondly, although some of the associations have been replicated in pre-school children (9), 366 
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primarily the candidate loci were relevant to an adult population, whereas this cohort were sampled 367 
and analysed at a much younger age. Finally, RWG has been associated with subsequent changes in 368 
BMI, whereas, Wahl and colleagues conclude that the majority of the identified BMI-related CpGs 369 
were a consequence (rather than a cause) of changes in BMI (12). Thus, if rapid growth was 370 
associated with DNA changes in this subset of CpGs, this perhaps would have been more likely to 371 
have been as a consequence of changes in BMI. Indeed, current evidence suggests that the direction 372 
of the effect is from BMI to DNAm (12, 51), therefore RWG (i.e. early life increases in BMI) 373 
associated DNAm changes may also be consequential of the phenotype rather than causal.  374 
Similar to Reed et al,. (51), we did not identify strong direct associations between childhood 375 
methylation at these CpGs and later BMI. They did however identify associations between a DNAm 376 
score for BMI and health outcomes where BMI is a risk factor, suggesting methylation may have 377 
more utility as a biomarker of BMI-related morbidity than as a predictor of BMI itself (51).  378 
 379 
Strengths and limitations  380 
A limitation of our study is the small sample size, however despite this, results were independently 381 
replicated at 1 of the CpGs.  It will be important to replicate these findings in other cohorts with 382 
much larger sample sizes and a range of ages. This study has a number of strengths, principally the 383 
rare combination of detailed early life phenotypic and anthropometric data, as well as epigenetic 384 
data, as cohorts with longitudinal and epigenetic data of this nature are scarce. Other studies will 385 
undoubtedly also be limited by the lack of available early life weight measures, and future birth 386 
cohort studies should strive to collect these vital data. Whilst our analysis may have been 387 
underpowered, robust associations were still identified, although it is possible that other 388 
differentially methylated sites may have been missed.  389 
Here we investigated RWG in the first year, however the entire childhood period could also be a 390 
critical period for growth and development of obesity (52). There is the possibility that associations 391 
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may be stronger in early life (before age 7), closer to the timing of the exposure, although this is not 392 
possible to test without multiple measures of DNAm throughout childhood. 393 
There were differences in the associations identified in the models with and without adjustment for 394 
cell types. Whole blood represents a mixed cell population with varying proportions of white blood 395 
cells. Phenotypic variation in cell-type composition could confound analyses, or it could also 396 
represent an important physiological change in response to an exposure or disease, which may be 397 
related to the phenotype of interest. Obesity is an acknowledged chronic, inflammatory condition, 398 
and has been associated with inflammatory indicators including C-reactive protein (53) and white 399 
blood cell counts (54, 55). When investigating biomarkers (related to an exposure) that are 400 
associated with an inflammatory disease outcome, to remove variation from cell counts could 401 
potentially disregard important loci.  402 
We utilised SVA and ISVA to remove unwanted variation from confounders (which cannot always be 403 
adequately corrected for), whilst retaining differences due to the exposure of interest (56). SVA finds 404 
sources of variation from the methylation data itself, and models these as linearly uncorrelated 405 
singular vectors (surrogate variables) which are then included as covariates in the regression model 406 
(33). ISVA is a modified version of SVA where surrogate variables are deemed independent. In 407 
support of ISVA, known confounding factors such as age and batch are linearly uncorrelated 408 
statistically independent variables, therefore it would be appropriate to model these as independent 409 
variables. ISVA was shown to perform best at capturing a known specific biological signature when 410 
compared to other adjustment methods (34), although this may not hold true for all datasets (34, 411 
57). A thorough simulation study comparing each of the common adjustment methods (Houseman’s 412 
reference-based method, RefFreeEWAS, SVA, ISVA, EWASher and RUV) and found no method 413 
performed perfectly for all parameters, but concluded SVA was most robust (and ‘safest’) (58). In 414 




Our findings suggest that differential DNAm at 2 loci could be markers of early weight gain. At one 417 
CpG site, the highest levels of childhood methylation were in those who had RWG in early life and 418 
were subsequently overweight/obese in childhood or adolescence, therefore this site may have use 419 
as a biomarker of subsequent overweight/obesity in those who experience RWG. The EWAS 420 
identified 2 potentially important candidate sites, which could be the focus of further investigation. 421 
Further work is required to determine if these CpG sites are consistently, differentially methylated in 422 
different populations, time points, and ages.  423 
 424 
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Figures  501 
 502 
 503 
Figure 1 Description and measurement of rapid infant weight gain exposures, and epigenome-wide DNA methylation and anthropometric outcomes, and an 504 
overview of the analysis. Participants were measured at around age 7 (mean 7.4 (SD 0.10) years) and 17 (mean 17.7 (SD 0.31) years). 505 
RWG, rapid weight gain; RT, rapid thrive; BMIz, BMI z-scores; OWOB, overweight/obese; DNAm, DNA methylation; EWAS, Epigenome-wide association study; 506 





   
Figure 2 Childhood methylation and adolescent body composition.  509 
Methylation at the cg01379158 locus (left plot), and cg11531579 (right plot). There were no  differences between groups for cg01379158 ANOVA (p>0.05).  510 
The cg11531579 plot presents tests for significance (p values) from the Kruskal Wallis test with Bonferroni correction for multiple testing.  511 








Figure 3 Pathways of mean methylation (cg11531579) at age 7 (%) and body composition (at ages 7 and 17).  516 
Dotted outline indicate the ‘high-risk’ individuals (i.e. those who had RWG and were subsequently overweight/obese (OWOB).  517 














































Figure 4 Change in methylation at the loci within individuals from age 7 to 17 by RWG. 522 
Test for differences using the Student’s t-test. Those who did not have RWG (n=60) demonstrated small mean increases (cg01379158, +0.6%; cg11531579, +1.2%) in 523 
methylation, whereas those who had RWG (n=34) demonstrated small (cg01379158, -0.4%; cg11531579, -0.6%) decreases in methylation between ages 7 and 17. Error 524 










































Supplementary text 526 
 527 
SWS Cohort 528 
The Southampton Women’s Survey (SWS) is an ongoing, prospective cohort study of 12,583, initially 529 
non-pregnant, women aged 20–34 years, living in the city of Southampton, UK (39). Assessments of 530 
lifestyle, diet and anthropometry were performed at study entry (April 1998–December 2002). 531 
Women who subsequently became pregnant were followed through pregnancy and their offspring 532 
through infancy and childhood. Follow-up of the children and sample collection/analysis was carried 533 
out under Institutional Review Board approval (Southampton and South West Hampshire Research 534 
Ethics Committee, references 276/97, 307/97, 153/99w, and 10/H0504/30) with written informed 535 
consent. Here we focus on the follow-up of the children aged 11-13 years which included epigenetic 536 
data. 537 
Early life measures 538 
Birth weights were recorded by midwives attending the birth and weight at 12 months using hospital 539 
digital scales (Seca Ltd, London) that were regularly calibrated. In order to adjust for sex and 540 
gestational age and also to compare with reference values for the population, birth weight 541 
measurements were expressed as z-scores compared with the 1990 British Growth Foundation (CGF) 542 
data, and were used to determine the rapid weight gain and rapid thrive variables. Rapid thrive was 543 
determined as z-score12m − r × z-scorebirth, where r was the cohort regression coefficient (r=0.276) of 544 
the linear model with z-score at 12month as the outcome with birthweight z-score as the exposure. 545 
RWG and RT were analysed as categorical variables of a >+0.67 standard deviation change. 546 
DNA extraction 547 
Genomic DNA (gDNA) was extracted from whole blood samples using the QIAamp Blood DNA mini 548 
kit (Qiagen). Quality of the genomic DNA was assessed by agarose gel electrophoresis and quantity 549 
of gDNA was checked on the NanoDrop ND-1000 (NanoDrop Technologies). 550 
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Infinium Human MethylationEPIC BeadChip array  551 
DNA methylation using the Infinium Human MethylationEPIC BeadChip array was used to 552 
interrogate DNA methylation in 107 whole blood samples. 1µg of the genomic DNA was treated with 553 
sodium bisulfite using Zymo EZ DNA Methylation-Gold kit (ZymoResearch, Irvine, California, USA, 554 
D5007) and processing of the Human MethylationEPIC (Infinium Methylation EPIC; Illumina, Inc. CA, 555 
USA) platform was carried out by the Centre for Molecular Medicine and Therapeutics (CMMT) 556 
(http://www.cmmt.ubc.ca). The idat files were processed in R v3.5.2. Estimation of white blood cell 557 
counts was done using the Houseman algorithm. CpGs with a high detection p-value (p>0.01), 558 
beadcount<3, cross-reactive and polymorphic probes identified by Pidsley et al., (59) and probes on 559 
sex chromosomes were removed prior to downstream analysis (final number of CpGs=792,718). 560 
However, only CpG sites that were differentially methylated (pFDR<0.05) in the ALSPAC analysis were 561 
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Supplementary tables and figures  569 
 570 
Table 1 Body composition of ARIES participants age 7 and 17 571 
 Age 7  Age 17 
 n Mean (SD)  n Mean (SD) 
BMIz 870 0.15(1.03) 
 
749 0.36(1.12) 
 n %  n % 
Healthy weight 753 87.25  597 80.68 
Overweight/obese 110 12.75  143 19.32 
Total 863     740   
Proportion (%) of study members in healthy weight or overweight/obese and mean BMIz and 572 
standard deviation (SD). n, sample size; %, column percentage. 573 
 574 
 575 
Table 2 Linear associations between CpG sites (age 7) and RT. 576 
Exposure n 
CpG name Chr Nearest 
gene Model Coefficient SE p value 
With cell counts            
RT 116 cg01379158 17 NT5M SVA 0.0078 0.0025 0.0022 
Without cell counts        
RT 125 cg01379158 12 NT5M SVA 0.0065 0.0025 0.0107 
RT 125 cg11531579 12 CHFR SVA 0.0056 0.0028 0.0493 
Models are adjusted for age, sex, and surrogate variables, both with or without adjustment for cell 577 
counts. Estimates represent beta coefficients. n, sample size; SE, standard error; SVA, surrogate 578 
variable analysis. 579 
 580 
  581 
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Table 3 Summary statistics of CpG methylation (age 7) at the identified differentially methylated loci (age 7) 582 
by phenotype (healthy weight not healthy weight) at ages 7 and 17 583 
    N Mean SD Median Min Max   N Mean SD Median Min Max 





74 0.069 0.017 0.068 0.033 0.125   74 0.035 0.011 0.033 0.016 0.084 




35 0.078 0.025 0.076 0.033 0.149  35 0.045 0.02 0.039 0.02 0.118 
OWOB 6 0.091 0.019 0.09 0.064 0.114  6 0.057 0.013 0.059 0.042 0.075 
 Total 125 0.073 0.021 0.073 0.033 0.149 
 125 0.04 0.015 0.035 0.016 0.118 
  p value 0.017             < 0.001           





54 0.069 0.017 0.069 0.039 0.103  54 0.036 0.012 0.033 0.023 0.084 




28 0.076 0.026 0.074 0.033 0.149  28 0.041 0.014 0.037 0.02 0.086 
OWOB 9 0.085 0.021 0.08 0.056 0.118  9 0.059 0.027 0.057 0.025 0.118 
 Total 110 0.072 0.02 0.071 0.033 0.149  110 0.039 0.015 0.035 0.016 0.118 
  p value 0.0801             < 0.001           
Values represent beta values. RWG, rapid weight gain; n, total in each group; SD, standard deviation; min, 584 
minimum; max, maximum. P value from ANOVA. Bold represents the high-risk phenotype of RWG in infancy 585 
and subsequent OWOB, which has higher DNAm levels (relative to the other categories). 586 











Figure I Q-Q plots for RWG models (SVA, ISVA) both with (A, B) and without (C,D) adjustment for cell counts.  588 
The Q-Q plots present the distribution of the p value for the association between CpG site methylation and RWG. The 589 
straight line is the expected distribution under the null hypothesis.   590 
  591 
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Age 7, RT 
 
 
Figure 2 Bi-directional Manhattan plots of the EWAS analysis of RWG and RT for the ISVA and SVA 
models without cell counts.  
The x-axis represents the chromosomes and the y-axis shows the –log10(P). The red line indicates the Bonferroni-corrected 
epigenome-wide threshold (p<1.04x10-7). Positively associated loci are displayed in the positive y-axis and negatively 
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